
Wolfgang A Schmidt

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11365872/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	EULAR recommendations for the reporting of ultrasound studies in rheumatic and musculoskeletal diseases (RMDs). Annals of the Rheumatic Diseases, 2021, 80, 840-847.	0.5	31
2	Quantitative ultrasound to monitor the vascular response to tocilizumab in giant cell arteritis. Rheumatology, 2021, 60, 5052-5059.	0.9	25
3	Ultrasound halo sign as a potential monitoring tool for patients with giant cell arteritis: a prospective analysis. Annals of the Rheumatic Diseases, 2021, 80, 1475-1482.	0.5	34
4	OMERACT definition and reliability assessment of chronic ultrasound lesions of the axillary artery in giant cell arteritis. Seminars in Arthritis and Rheumatism, 2021, 51, 951-956.	1.6	13
5	Efficacy and safety of secukinumab in patients with giant cell arteritis: study protocol for a randomized, parallel group, double-blind, placebo-controlled phase II trial. Trials, 2021, 22, 543.	0.7	31
6	Ultrasound for diagnosis and follow-up of chronic axillary vasculitis in patients with long-standing giant cell arteritis. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2199850.	1.2	14
7	Ultrasonographic Halo Score in giant cell arteritis: association with intimal hyperplasia and ischaemic sight loss. Rheumatology, 2021, 60, 4361-4366.	0.9	15
8	Introduction: Musculoskeletal Ultrasound Indications and Fundamentals. , 2021, , 1-20.		1
9	Disease stratification in giant cell arteritis to reduce relapses and prevent long-term vascular damage. Lancet Rheumatology, The, 2021, 3, e886-e895.	2.2	15
10	The impact of disease extent and severity detected by quantitative ultrasound analysis in the diagnosis and outcome of giant cell arteritis. Rheumatology, 2020, 59, 2299-2307.	0.9	21
11	Imaging in large-vessel vasculitis. Best Practice and Research in Clinical Rheumatology, 2020, 34, 101589.	1.4	15
12	Early variation of ultrasound halo sign with treatment and relation with clinical features in patients with giant cell arteritis. Rheumatology, 2020, 59, 3717-3726.	0.9	26
13	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summary. Rheumatology, 2020, 59, 487-494.	0.9	56
14	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. Rheumatology, 2020, 59, e1-e23.	0.9	128
15	Temporal arteritis with ultrasound halo sign in eosinophilic granulomatosis with polyangiitis. Rheumatology, 2019, 58, 2069-2071.	0.9	8
16	Clinical Applicability of Ultrasound in Systemic Large Vessel Vasculitides. Arthritis and Rheumatology, 2019, 71, 1780-1787.	2.9	19
17	The ultrasound halo sign of temporal arteries: is it always giant cell arteritis?. Rheumatology, 2019, 58, 1898-1899.	0.9	18
18	OMERACT Definitions for Ultrasonographic Pathologies and Elementary Lesions of Rheumatic Disorders 15 Years On. Journal of Rheumatology, 2019, 46, 1388-1393.	1.0	133

#	Article	IF	CITATIONS
19	2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritis. Annals of the Rheumatic Diseases, 2019, 78, 1160-1166.	0.5	34
20	FRI0274â€ULTRASOUND CUT-OFF VALUE FOR INTIMA-MEDIA THICKNESS OF THE AXILLARY ARTERIES IN PATIEN WITH CHRONIC LARGE-VESSEL GIANT CELL ARTERITIS. , 2019, , .	NTS	0
21	Response to: â€~The role of temporal artery biopsy in patients with giant cell arteritis is debated' by Moiseev et al. Annals of the Rheumatic Diseases, 2019, 78, e32-e32.	0.5	1
22	Ultrasound in the diagnosis and management of giant cell arteritis. Rheumatology, 2018, 57, ii22-ii31.	0.9	139
23	Atherosclerosis as a potential pitfall in the diagnosis of giant cell arteritis. Rheumatology, 2018, 57, 318-321.	0.9	60
24	EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Annals of the Rheumatic Diseases, 2018, 77, 636-643.	0.5	753
25	The use of ultrasound to assess giant cell arteritis: review of the current evidence and practical guide for the rheumatologist. Rheumatology, 2018, 57, 227-235.	0.9	101
26	The proposed role of ultrasound in the management of giant cell arteritis in routine clinical practice. Rheumatology, 2018, 57, 112-119.	0.9	53
27	Investigations in systemic vasculitis – The role of imaging. Best Practice and Research in Clinical Rheumatology, 2018, 32, 63-82.	1.4	25
28	Assessing Vasculitis in Giant Cell Arteritis by Ultrasound: Results of OMERACT Patient-based Reliability Exercises. Journal of Rheumatology, 2018, 45, 1289-1295.	1.0	49
29	Definitions and reliability assessment of elementary ultrasound lesions in giant cell arteritis: a study from the OMERACT Large Vessel Vasculitis Ultrasound Working Group. RMD Open, 2018, 4, e000598.	1.8	155
30	Ultrasound cut-off values for intima-media thickness of temporal, facial and axillary arteries in giant cell arteritis. Rheumatology, 2017, 56, 1479-1483.	0.9	122
31	Scoring ultrasound synovitis in rheumatoid arthritis: a EULAR-OMERACT ultrasound taskforce-Part 2: reliability and application to multiple joints of a standardised consensus-based scoring system. RMD Open, 2017, 3, e000427.	1.8	149
32	The 2017 EULAR standardised procedures for ultrasound imaging in rheumatology. Annals of the Rheumatic Diseases, 2017, 76, 1974-1979.	0.5	191
33	Imaging of vasculitis: State of the art. Best Practice and Research in Clinical Rheumatology, 2016, 30, 688-706.	1.4	64
34	The Role of Ultrasound Compared to Biopsy of Temporal Arteries in the Diagnosis and Treatment of Giant Cell Arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study. Health Technology Assessment, 2016, 20, 1-238.	1.3	313
35	International Consensus for ultrasound lesions in gout: results of Delphi process and web-reliability exercise. Rheumatology, 2015, 54, 1797-1805.	0.9	122
36	Ultrasound in Rheumatology. International Journal of Rheumatic Diseases, 2014, 17, 711-715.	0.9	4

WOLFGANG A SCHMIDT

#	Article	IF	CITATIONS
37	Whole-body MRI in RA: do we still need the rheumatologist?. Nature Reviews Rheumatology, 2014, 10, 130-132.	3.5	2
38	Role of ultrasound in the understanding and management of vasculitis. Therapeutic Advances in Musculoskeletal Disease, 2014, 6, 39-47.	1.2	82
39	Imaging in vasculitis. Best Practice and Research in Clinical Rheumatology, 2013, 27, 107-118.	1.4	74
40	EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2013, 72, 804-814.	0.5	504
41	The US7 score is sensitive to change in a large cohort of patients with rheumatoid arthritis over 12â€months of therapy. Annals of the Rheumatic Diseases, 2013, 72, 1163-1169.	0.5	77
42	The Diagnosis and Treatment of Giant Cell Arteritis. Deutsches Ärzteblatt International, 2013, 110, 376-85; quiz 386.	0.6	100
43	The new frontiers of ultrasound in the complex world of vasculitides and scleroderma. Rheumatology, 2012, 51, vii26-vii30.	0.9	17
44	Head-to-head comparison of quantitative and semi-quantitative ultrasound scoring systems for rheumatoid arthritis: reliability, agreement and construct validity. Rheumatology, 2012, 51, 2034-2038.	0.9	30
45	2012 Provisional classification criteria for polymyalgia rheumatica: A European League Against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis and Rheumatism, 2012, 64, 943-954.	6.7	273
46	Ultrasonography in inflammatory rheumatic disease: an overview. Nature Reviews Rheumatology, 2011, 7, 479-488.	3.5	38
47	The OMERACT Ultrasound Task Force — Status and Perspectives. Journal of Rheumatology, 2011, 38, 2063-2067.	1.0	111
48	Polymyalgia Rheumatica and Giant Cell Arteritis in the Elderly. , 2011, , 225-229.		0
49	Current state of musculoskeletal ultrasound training and implementation in Europe: results of a survey of experts and scientific societies. Rheumatology, 2010, 49, 2438-2443.	0.9	65
50	Reliability Exercise for the Polymyalgia Rheumatica Classification Criteria Study: The Oranjewoud Ultrasound Substudy. International Journal of Rheumatology, 2009, 2009, 1-5.	0.9	23
51	Do temporal artery duplex ultrasound findings correlate with ophthalmic complications in giant cell arteritis?. Rheumatology, 2009, 48, 383-385.	0.9	46
52	What the practising rheumatologist needs to know about the technical fundamentals of ultrasonography. Best Practice and Research in Clinical Rheumatology, 2008, 22, 981-999.	1.4	17
53	Technology Insight: the role of color and power Doppler ultrasonography in rheumatology. Nature Clinical Practice Rheumatology, 2007, 3, 35-42.	3.2	52
54	Current diagnosis and treatment of temporal arteritis. Current Treatment Options in Cardiovascular Medicine, 2006, 8, 145-151.	0.4	20

Wolfgang A Schmidt

#	Article	IF	CITATIONS
55	Takayasu and Temporal Arteritis. , 2006, 21, 96-104.		23
56	Role of imaging in diagnosis of and differentiation between vasculitides. Future Rheumatology, 2006, 1, 627-634.	0.2	10
57	Use of ultrasonography and positron emission tomography in the diagnosis and assessment of large-vessel vasculitis. Current Opinion in Rheumatology, 2005, 17, 9-15.	2.0	115
58	Meta-Analysis: Test Performance of Ultrasonography for Giant-Cell Arteritis. Annals of Internal Medicine, 2005, 142, 359.	2.0	323
59	What is the best approach to diagnosing large-vessel vasculitis?. Best Practice and Research in Clinical Rheumatology, 2005, 19, 223-242.	1.4	78
60	Musculoskeletal ultrasound including definitions for ultrasonographic pathology. Journal of Rheumatology, 2005, 32, 2485-7.	1.0	848
61	Doppler sonography in rheumatology. Best Practice and Research in Clinical Rheumatology, 2004, 18, 827-846.	1.4	35
62	Color Duplex Ultrasonography in the Diagnosis of Temporal Arteritis. New England Journal of Medicine, 1997, 337, 1336-1342.	13.9	660